Neurogene Inc. (NGNE) Financial Statements
Neurogene Inc. (NGNE) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$111.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$87.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NGNENeurogene Inc.Follow NGNE — free
—
Price chart with a free account
- Market cap
- 471.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 25.0 | 0.9 | 0.0 | — | |
| Research & development | 41.8 | 60.9 | 75.0 | 88.5 | |
| Operating income | -32.6 | -82.6 | -103.3 | -121.3 | |
| Pre-tax income | -31.6 | -75.1 | -90.4 | -111.1 | |
| Income tax | — | 0.0 | 0.0 | — | |
| Net income | -31.6 | -75.1 | -90.4 | -111.1 | |
| Diluted EPS ($) | -1.34 | -4.28 | -4.24 | -5.04 | |
| Diluted shares (mn) | — | 17.6 | 21.3 | — |
USD millions · SEC XBRL
Neurogene Inc. — questions
- What is Neurogene Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Neurogene Inc.'s net income?
- -$111.1M over the twelve months to 2026-06-30.
- What is Neurogene Inc.'s free cash flow?
- -$87.7M over the twelve months to 2026-06-30.
- What are Neurogene Inc.'s diluted earnings per share?
- $-5.04 over the twelve months to 2026-06-30.
Every figure on this page comes from Neurogene Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.